Compares pacing with node ablation to drug therapy for atrial fibrillation
Compares pacemaker pacing plus AV node ablation with drugs in older adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT06699342
- Record updated
- 20 August 2026
- Original description
This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.Read full original descriptionShow less
Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation
This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.
Inclusion:; Patients who meet all of the following inclusion criteria 1)-6); Permanent atrial fibrillation; Age ≥ 65 years; Refractory or intolerant to antiarrhythmic drugs, rate control medications, or catheter ablation; New York Heart Association (NYHA) functional class II- IV; LVEF > 40% (within the past 3 months); Patients with at least one of the following:; HF hospitalization (defined as HF as the major reason for hospitalization or treatment for HF lasting ≥12 hours and including treatment with intravenous (IV) diuretics at a healthcare facility) within 12 months; Elevated NT-proBNP (>900 pg/ml) in the 30 days prior to enrollment; Exclusion:; Patients who meet at least one of the following exclusion criteria 1)-11); Asymptomatic atrial fibrillation; Life expectancy to < 12 months; Primary moderate to severe valvular disease (except for functional mitral valve regurgitation or tricuspid valve regurgitation); Mechanical tricuspid valve replacement; Severe chronic kidney disease (estimated Glomerular Filtration Rate ≤ 15 ml/1,73 m2 or receiving renal replacement treatment including hemodialysis or peritoneal dialysis); Obstructive hypertrophic cardiomyopathy; Infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others); Acute coronary syndrome or coronary revascularization (CABG or PCI) <3 months; Severe primary pulmonary disease such as cor pulmonale, irreversible lung disease requiring inhalers, oxygen supplementation; Pacemaker/ICD/CRT treatment ongoing, or current pacemaker indication; Simultaneous participation in a different randomized clinical trial.